Amarin Rises On Priority Review For Vascepa Label Expansion
Zacks Investment Research | May 30, 2019 08:28AM ET
Amarin Corporation plc (NASDAQ:AMRN) announced that the FDA has granted priority review to the supplemental new drug application (sNDA) for its sole marketed drug, Vascepa. The sNDA is looking to expand Vascepa’s label as a treatment for reduction of residual cardiovascular risk in patients with persistent elevated triglycerides on statin therapy for LDL-C (bad cholesterol). A decision on approval is expected by Sep 28, 2019.
A potential approval to the label expansion will make Vascepa the first drug for the indication.
Please note that Vascepa is already approved in the United States as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia.
Shares of Amarin rallied 11.6% on May 29 following the news. Amarin’s shares have gained 29.6% so far this year compared with the industry ’s increase of 0.9%.
The sNDA includes data from the late-stage cardiovascular outcomes study – REDUCE-IT. In March, Amarin presented updated data from the study, which showed that the drug led to a significant reduction in cardiovascular risk in patients with LDL-C controlled by statin therapy. The relative risk of major adverse CV events (“MACE”) was reduced by 30% upon treatment with Vascepa compared to placebo.
Vascepa also led to a 26% reduction in key secondary composite endpoint of cardiovascular death, heart attacks and stroke. The study also achieved the additional secondary endpoints including reductions in cardiovascular death (20%), fatal or nonfatal heart attacks (31%), fatal or nonfatal stroke (28%), urgent or emergent coronary revascularization (35%) and hospitalization for unstable angina (32%).
Upon potential approval, the drug will face competition from Sanofi (NASDAQ:SNY) and Amgen’s (NASDAQ:AMGN) PCSK9 inhibitors, Praluent and Repatha, respectively.
Amarin Corporation PLC Price
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.